In a report issued on July 29, Daina Graybosch from Leerink Partners maintained a Buy rating on Genocea Biosciences (GNCA – Research Report), with a price target of $6.00. The company’s shares closed last Friday at $2.02, close to its 52-week low of $1.80.
According to TipRanks.com, Graybosch is a 3-star analyst with an average return of 8.9% and a 48.3% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Werewolf Therapeutics, Inc., Silverback Therapeutics, and Bolt Biotherapeutics.
Currently, the analyst consensus on Genocea Biosciences is a Strong Buy with an average price target of $7.67, implying a 279.7% upside from current levels. In a report issued on July 14, Robert W. Baird also maintained a Buy rating on the stock with a $8.00 price target.
Based on Genocea Biosciences’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $4.31 million. In comparison, last year the company earned revenue of $906K and had a GAAP net loss of $11.32 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.